New Recruiting Trial: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
WHY IT MATTERS
This trial is recruiting adults who previously responded to ianalumab for ITP or wAIHA, offering a potential path to continued access for patients whose symptoms improved on this treatment.
Novartis is looking for adults who have immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) — two blood disorders where the immune system attacks blood cells — and who previously did well on a drug called ianalumab. This new study will test whether ianalumab continues to work for these patients. The trial is expected to start in April 2026.
NCT ID: NCT07039422 Title: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Status: RECRUITING Phase: PHASE2 Sponsor: Novartis Pharmaceuticals Start date: 2026-04-27 URL: https://clinicaltrials.gov/study/NCT07039422 Source: UniteRare clinical trials database
ASK YOUR DOCTOR
If you have ITP or wAIHA and previously benefited from ianalumab, ask your doctor whether you might be eligible for this trial and how to inquire about enrollment.